Latest News

Jensen Huang called Marvell the next trillion-dollar stock at the Computex conference in June.

Walmart won't offer much in terms of income, but its ability to boost dividend payouts for 53 consecutive years shows the strength of its business model.

Carbon storage and fuel cell plans advance as pipeline restart nears.

A Democratic sweep and a new Texas governor who wants to pause data center construction sent AI-infrastructure stocks tumbling. Here's what changed, and what didn't.

Platform migrations and larger deal sizes drove the quarter's momentum.

Europe competition squeezed margins even as the fleet grew 26 percent.

Revenue fell 6.2% as past sales lags weighed on results, with 2027 expected softer.

Gross margin rose 230 basis points as AI platforms reshaped delivery productivity.

China sales slump and a restructuring plan reshape the outlook

Revenue fell as a key customer paused orders, yet new OEM programs are emerging.

Chicago licenses are in hand as Illinois results improved on a sharper location mix.

Management cut 2026 cash guidance as its MOBIUS line nears full commissioning.

Management details why market penetration under 4% signals runway.

A beat-and-raise quarter wasn't enough to buoy the cloud monitoring and security platform.

Shopify's selloff offers a cheaper entry into a growing business, but a 10-year TFSA still needs price discipline.

The neocloud company is going to face headwinds in data center construction.

One just showed a real sign its turnaround is working, while the other's earnings beat hid a weaker underlying story.

Margin gains and a shifting robotic surgery outlook shape the quarter.

Diesel costs and a critical mineral push frame Ramaco's latest quarter.

Debt cuts and $100 million in free cash flow offset mortgage headwinds this quarter.

Working capital absorbed $80 million even as segment operating income climbed.

Navitas expects high-power markets to dominate revenue by year-end.

Operations beyond Puerto Rico now generate nearly half of revenue.

Margins hit an eight-year high, but cash collections are slipping into next year.

Biopharma overtook academia as top revenue source, and full-year guidance rose.